Novo Nordisk Foundation: New European initiative to accelerate drug discovery for cardiometabolic diseases
The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs). The initiative addresses one of today’s most pressing global challenges: Translating promising research into improved care for people living with CMDs.
Despite Europe’s strong position in CMD research, many promising discoveries fail to progress beyond the academic laboratory. To address this challenge, a new initiative, CardioMetabolic Bridge, will support selected academic research projects with funding, scientific and commercial mentoring from entrepreneurs and industry experts and access to state-of-the-art facilities.
